Loading...

Thomas Martin, III, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue
San Francisco CA 94117
Phone415-353-2421
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPost-Doc Fellow/Scholar1996 Medicine
    University of California, San Francisco Clinical Fellowship
    University of California, San FranciscoResidency
    University of ConnecticutM.D.1989School of Medicine

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma. Clin Cancer Res. 2020 Sep 11. Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann B, Wolf JL, Martin TG, Liu B. PMID: 32917735.
      View in: PubMed   Mentions:    Fields:    
    2. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020 Jul 14; 4(13):2899-2911. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. PMID: 32589729.
      View in: PubMed   Mentions:    Fields:    
    3. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nat Commun. 2020 04 22; 11(1):1931. Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. PMID: 32321912.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    4. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020 Jan 14; 4(1):181-190. Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W. PMID: 31935283.
      View in: PubMed   Mentions:    Fields:    
    5. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2020 May; 26(5):876-883. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG. PMID: 31785375.
      View in: PubMed   Mentions: 1     Fields:    
    6. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells. 2019 11 26; 8(12). Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC. PMID: 31779273.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    7. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020 03; 34(3):938-941. Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP. PMID: 31595037.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    8. Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2020 01; 26(1):189-196. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. PMID: 31493541.
      View in: PubMed   Mentions: 3     Fields:    
    9. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma. Mol Cancer Ther. 2019 11; 18(11):2008-2020. Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, Kamperschroer C, Pascua E, Chen W, Delaria K, Farias S, Bateman M, Dushin RG, Chin SM, Van Blarcom TJ, Yeung YA, Lindquist KC, Chunyk AG, Kuang B, Han B, Mirsky M, Pardo I, Buetow B, Martin TG, Wolf JL, Shelton D, Rajpal A, Strop P, Chaparro-Riggers J, Sasu BJ. PMID: 31434693.
      View in: PubMed   Mentions:
    10. Multiple Myeloma: Current Advances and Future Directions. Clin Lymphoma Myeloma Leuk. 2019 05; 19(5):255-263. Martin T, Huff CA. PMID: 31130488.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    11. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 06; 25(6):1218-1224. Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL. PMID: 30708189.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    12. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):9-22. Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. PMID: 30287200.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma. J Oncol Pharm Pract. 2019 Jul; 25(5):1253-1257. Tan M, Kalin-Hajdu E, Narayan R, Wong SW, Martin TG. PMID: 30005587.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Mol Cancer Ther. 2017 11; 16(11):2375-2386. Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M. PMID: 28878026.
      View in: PubMed   Mentions:
    15. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leuk Lymphoma. 2017 08; 58(8):1872-1879. Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C. PMID: 28140719.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    16. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. PMID: 27841764.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    17. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. PMID: 27587788.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    18. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 11; 22(11):1974-1982. Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. PMID: 27544285.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 05 26; 127(21):2561-8. Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. PMID: 26932802.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    20. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 06; 22(6):1030-1036. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. PMID: 26899561.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    21. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 07; 57(7):1560-6. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. PMID: 26490487.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. PMID: 25776193.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    23. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. PMID: 25294123.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    24. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. PMID: 25243620.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    25. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. PMID: 24894413.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology (Williston Park). 2013 Dec; 27 Suppl 3:4-10. Martin TG. PMID: 25184230.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. PMID: 23447001.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    28. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. PMID: 22571201.
      View in: PubMed   Mentions: 282     Fields:    Translation:HumansCTClinical Trials
    29. Autologous hematopoietic cell transplantation for high-risk ALL. Bone Marrow Transplant. 2011 Mar; 46(3):460-1. Linker C, Damon L, Martin T, Blume K, Forman S, Snyder D, Wolf J, Negrin R. PMID: 20531287.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008 Nov; 42(10):649-57. Damon L, Damon LE, Gaensler K, Kaplan L, Martin T, Rubenstein J, Linker C. PMID: 18679366.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    31. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. PMID: 17989720.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    32. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006 Sep; 38(6):421-6. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. PMID: 16892072.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    33. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar; 12(3):316-24. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. PMID: 16503501.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004 Aug 01; 104(3):649-54. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. PMID: 15069017.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    35. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia. 2003 Dec; 17(12):2538-40. Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. PMID: 14523458.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2003 Oct; 9(10):643-8. Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, Linker C. PMID: 14569560.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    37. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003 Oct 15; 102(8):3052-9. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. PMID: 12842990.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    38. Adaptive decision making in a lymphocyte infusion trial. Biometrics. 2002 Sep; 58(3):560-8. Thall PF, Inoue LY, Martin TG. PMID: 12229990.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    39. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. PMID: 11996478.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    40. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):121-43. Martin TG, Linker CA. PMID: 11253604.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease. Bone Marrow Transplant. 2001 Feb; 27(4):355-64. Muench MO, Rae J, Bárcena A, Leemhuis T, Farrell J, Humeau L, Maxwell-Wiggins JR, Capper J, Mychaliska GB, Albanese CT, Martin T, Tsukamoto A, Curnutte JT, Harrison MR. PMID: 11313664.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    42. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):97-120. Martin TG, Gajewski JL. PMID: 11253611.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    43. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2001; 7(10):568-75. Shimoni A, Gajewski JA, Donato M, Martin T, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S. PMID: 11760089.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    44. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol. 2000 Jun; 109(4):770-2. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin RE, Körbling M. PMID: 10929027.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    45. Interferon-induced thrombocytopenia: is it time for thrombopoietin. Hepatology. 1998 Nov; 28(5):1430-2. Martin TG, Shuman MA. PMID: 9794932.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med. 1997 Aug 15; 127(4):285-8. Martin TG, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA. PMID: 9265428.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    47. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. Br J Haematol. 1996 Dec; 95(3):535-41. Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL. PMID: 8943898.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1991 Nov; 9(11):1939-44. Dimery IW, Brooks BJ, Winn R, Martin T, Shirinian M, Hong WK. PMID: 1941052.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    Thomas's Networks
    Concepts (248)
    Derived automatically from this person's publications.
    _
    Co-Authors (42)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _